InvestorsHub Logo
Followers 7
Posts 234
Boards Moderated 0
Alias Born 08/18/2018

Re: Amrsto1000 post# 338192

Monday, 04/26/2021 11:30:17 AM

Monday, April 26, 2021 11:30:17 AM

Post# of 345830
ENHANZE® Drives 86% Year-over-year and 34% Sequential Growth in Royalties in the Fourth Quarter -
- 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue -
- 2021 Royalties Projected to Double versus 2020 Royalties -
- 2021 EPS Guidance of $1.40 to $1.55 Representing 54%-70% Growth over 2020 EPS -

SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News